Stifel analyst Ben Burnett reiterated a Buy rating on Mirati Therapeutics (NASDAQ: MRTX), following the company's ASCO presentations. The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE